Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05631704 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity
A Phase 1 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT05631704 is a Phase 1 study that has completed, run by ViiV Healthcare. The registered enrollment target is 84 participants.
The verdict
NCT05631704, a Phase 1 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
This study is designed to investigate the safety, tolerability and PK of VH4524184 (GSK4524184) and the potential of VH4524184 to inhibit or induce CYP3A activity in healthy participants.
Interventions
- DRUG Placebo
- DRUG Midazolam
- DRUG VH4524184
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2022-12-02 |
| Est. Completion | 2023-07-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05631704
The ClinicalTrials.gov registry entry for NCT05631704 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05631704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05631704 about?
NCT05631704 is a clinical study titled "A Study to Investigate Safety, Tolerability, and Pharmacokinetics (PK) of VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity". This study is designed to investigate the safety, tolerability and PK of VH4524184 (GSK4524184) and the potential of VH4524184 to inhibit or induce CYP3A activity in healthy participants.
What is the current status of trial NCT05631704?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2022-12-02. Estimated completion is 2023-07-27.
What interventions are being tested in trial NCT05631704?
The interventions under investigation include: Placebo (DRUG), Midazolam (DRUG), VH4524184 (DRUG).
Who is sponsoring clinical trial NCT05631704?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.